Search

Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)

Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A Virus A/Sydney/5/2021 SAN-013 (H1N1) antigen (formaldehyde inactivated)

Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated)

Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (propiolactone inactivated)

Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (propiolactone inactivated)

Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (UV, formaldehyde inactivated)

Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (propiolactone inactivated)

Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Zenarestat

Linsitinib

An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. … IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.

Telapristone acetate

Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.